NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 03 03:45PM ET
0.4400
Dollar change
0.0000
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.51 Insider Own48.11% Shs Outstand24.97M Perf Week-2.22%
Market Cap11.52M Forward P/E- EPS next Y-1.44 Insider Trans0.00% Shs Float13.58M Perf Month-12.18%
Enterprise Value18.38M PEG- EPS next Q-0.26 Inst Own34.45% Short Float1.74% Perf Quarter-30.05%
Income-16.15M P/S- EPS this Y61.16% Inst Trans-8.30% Short Ratio1.58 Perf Half Y-37.13%
Sales0.00M P/B1.88 EPS next Y-10.34% ROA-25.38% Short Interest0.24M Perf YTD-39.73%
Book/sh0.23 P/C0.55 EPS next 5Y22.65% ROE-68.18% 52W High3.86 -88.61% Perf Year-87.10%
Cash/sh0.80 P/FCF- EPS past 3/5Y52.69% 47.40% ROIC-49.46% 52W Low0.34 29.41% Perf 3Y-94.02%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility9.99% 10.88% Perf 5Y-99.22%
Dividend TTM- EV/Sales- EPS Y/Y TTM89.52% Oper. Margin- ATR (14)0.05 Perf 10Y-
Dividend Ex-Date- Quick Ratio3.35 Sales Y/Y TTM- Profit Margin- RSI (14)43.33 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio3.35 EPS Q/Q88.08% SMA20-2.46% Beta1.43 Target Price15.50
Payout- Debt/Eq0.38 Sales Q/Q- SMA50-13.84% Rel Volume0.78 Prev Close0.44
Employees57 LT Debt/Eq0.33 EarningsMay 15 BMO SMA200-35.99% Avg Volume149.56K Price0.44
IPOMar 13, 2019 Option/ShortNo / Yes EPS/Sales Surpr.8.33% - Trades Volume116,986 Change0.00%
Date Action Analyst Rating Change Price Target Change
Apr-15-21Initiated Ladenburg Thalmann Buy $25
May-19-25 10:02AM
May-16-25 03:13AM
May-15-25 06:30AM
May-08-25 07:00AM
Apr-18-25 09:55AM
06:30AM Loading…
Apr-01-25 06:30AM
Mar-31-25 06:30AM
Mar-25-25 06:30AM
Mar-19-25 12:35PM
Feb-26-25 08:00AM
Dec-16-24 08:00AM
Nov-14-24 06:30AM
Nov-12-24 12:20PM
Oct-16-24 07:05AM
Oct-15-24 07:00AM
08:00AM Loading…
Sep-18-24 08:00AM
Sep-04-24 08:00AM
Sep-03-24 08:00AM
Aug-16-24 10:55AM
Aug-15-24 06:30AM
06:30AM
Aug-08-24 07:00AM
Jul-29-24 07:00AM
Jul-10-24 06:30AM
May-30-24 04:50PM
07:00AM
May-21-24 06:30AM
May-15-24 07:00AM
May-06-24 07:00AM
Apr-23-24 08:00AM
08:00AM Loading…
Apr-18-24 08:00AM
Apr-05-24 09:55AM
Apr-04-24 07:49AM
Apr-03-24 06:30AM
Mar-27-24 06:30AM
Mar-19-24 05:00AM
Mar-18-24 06:30AM
Mar-06-24 07:30AM
Jan-04-24 08:00AM
Nov-30-23 04:15PM
Nov-29-23 06:30AM
Nov-14-23 06:30AM
Oct-27-23 08:00AM
Oct-18-23 08:00AM
Oct-04-23 06:34AM
Sep-07-23 09:00AM
Sep-06-23 04:05PM
Aug-09-23 06:30AM
Aug-02-23 04:30PM
Jun-08-23 05:00PM
May-31-23 03:00AM
May-15-23 06:30AM
May-12-23 08:00AM
May-08-23 06:30AM
May-05-23 06:30AM
Mar-29-23 06:30AM
Mar-27-23 07:00AM
Feb-22-23 06:35AM
06:30AM
Nov-29-22 09:10AM
Nov-09-22 06:30AM
Nov-02-22 09:00AM
Sep-11-22 07:22AM
Aug-10-22 06:30AM
Aug-07-22 03:17AM
Aug-04-22 11:20AM
Jul-06-22 01:45AM
Jun-28-22 06:30AM
Jun-27-22 06:30AM
May-24-22 01:52AM
May-20-22 08:00AM
May-11-22 06:30AM
May-06-22 07:00AM
May-05-22 08:00AM
Mar-30-22 06:30AM
Mar-23-22 08:00AM
Feb-24-22 08:00AM
Jan-04-22 07:00AM
Nov-17-21 08:00AM
Nov-15-21 06:00AM
Nov-09-21 08:00AM
Oct-25-21 10:00AM
Oct-18-21 07:00AM
Oct-13-21 07:00AM
Sep-02-21 04:05PM
Aug-16-21 06:30AM
Aug-12-21 08:00AM
Jul-26-21 08:13AM
Jun-14-21 06:30AM
Jun-09-21 06:30AM
May-25-21 10:46AM
May-24-21 06:30AM
06:15AM
May-18-21 08:00AM
06:30AM
Apr-20-21 07:00AM
Mar-31-21 06:30AM
05:45AM
Mar-24-21 06:30AM
Mar-02-21 07:00AM
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EDirectorFeb 27 '25Option Exercise0.93706,498657,4671,247,054Mar 03 07:02 PM